Intellia Therapeutics Inc [NASDAQ: NTLA] loss -5.60% or -0.69 points to close at $11.64 with a heavy trading volume of 6801249 shares.
It opened the trading session at $12.02, the shares rose to $12.275 and dropped to $11.46, the range by which the price of stock traded the whole day. The daily chart for NTLA points out that the company has recorded 15.02% gains over the past six months.
If we look at the average trading volume of 4.88M shares, NTLA reached to a volume of 6801249 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Intellia Therapeutics Inc [NTLA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $36.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Intellia Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 21, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 05, 2025, representing the official price target for Intellia Therapeutics Inc stock. Previously, the target price had yet another drop from $45 to $13, while JP Morgan kept a Neutral rating on NTLA stock.
The Price to Book ratio for the last quarter was 1.55, with the Price to Cash per share for the same quarter was set at 4.86.
Trading performance analysis for NTLA stock
Intellia Therapeutics Inc [NTLA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.92. With this latest performance, NTLA shares gained by 17.81% in over the last four-week period, additionally plugging by 15.02% over the last 6 months – not to mention a drop of -0.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 50.00, with the RSI for the last a single of trading hit 0.95, and the three-weeks RSI is set at 0.87 for Intellia Therapeutics Inc [NTLA]. The present Moving Average for the last 50 days of trading for this stock 10.18, while it was recorded at 12.64 for the last single week of trading, and 11.17 for the last 200 days.
Intellia Therapeutics Inc [NTLA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc [NTLA] shares currently have an operating margin of -1173.09% and a Gross Margin at 77.46%. Intellia Therapeutics Inc’s Net Margin is presently recorded at -1154.10%.
Intellia Therapeutics Inc (NTLA) Capital Structure & Debt Analysis
According to recent financial data for Intellia Therapeutics Inc. ( NTLA), the Return on Equity (ROE) stands at -57.92%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -46.84%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Intellia Therapeutics Inc’s Return on Invested Capital (ROIC) is -61.12%, showcasing its effectiveness in deploying capital for earnings.
Intellia Therapeutics Inc (NTLA) Efficiency & Liquidity Metrics
Based on Intellia Therapeutics Inc’s (NTLA) latest financial statements, the Debt-to-Equity Ratio is 0.15%, indicating its reliance on debt financing relative to shareholder equity.
Intellia Therapeutics Inc (NTLA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Intellia Therapeutics Inc. (NTLA) effectively leverages its workforce, generating an average of -$1304987.59 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.90% and a Quick Ratio of 4.90%, indicating strong ability to cover short-term liabilities.
Intellia Therapeutics Inc [NTLA]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc go to 30.65%.
An analysis of Institutional ownership at Intellia Therapeutics Inc [NTLA]
There are presently around $93.37%, or 98.25%% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11.6 million shares, which is approximately 11.9575%. BLACKROCK INC., holding 9.6 million shares of the stock with an approximate value of $$214.79 million in NTLA stocks shares; and BLACKROCK INC., currently with $$203.66 million in NTLA stock with ownership which is approximately 9.3839%.
